blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2877494

EP2877494 - PTPRS AND PROTEOGLYCANS IN AUTOIMMUNE DISEASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.05.2021
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  12.06.2020
FormerGrant of patent is intended
Status updated on  23.01.2020
FormerExamination is in progress
Status updated on  09.03.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
La Jolla Institute for Allergy and Immunology
9420 Athena Circle
La Jolla, CA 92037 / US
[2015/23]
Inventor(s)01 / BOTTINI, Nunzio
c/o La Jolla Institute for Allergy&Immunology
9420 Athena Circle
La Jolla, CA 92037 / US
02 / STANFORD, Stephanie
9229 Regents Road
L209
La Jolla, CA 92037 / US
 [2015/23]
Representative(s)Boult Wade Tennant LLP
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP / GB
[2020/29]
Former [2015/23]Boult Wade Tennant
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT / GB
Application number, filing date13823022.223.07.2013
[2020/29]
WO2013US51723
Priority number, dateUS201261674853P23.07.2012         Original published format: US 201261674853 P
US201261675036P24.07.2012         Original published format: US 201261675036 P
US201361832688P07.06.2013         Original published format: US 201361832688 P
[2015/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014018554
Date:30.01.2014
Language:EN
[2014/05]
Type: A1 Application with search report 
No.:EP2877494
Date:03.06.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 30.01.2014 takes the place of the publication of the European patent application.
[2015/23]
Type: B1 Patent specification 
No.:EP2877494
Date:15.07.2020
Language:EN
[2020/29]
Search report(s)International search report - published on:KR30.01.2014
(Supplementary) European search report - dispatched on:EP17.03.2016
ClassificationIPC:C07K16/40, G01N33/573, A61K39/395, A61P37/00, C07K14/705, C07K16/18, C12N9/16
[2016/16]
CPC:
C12N9/16 (EP,US); A61K39/395 (EP,US); A61P37/00 (EP);
C07K14/705 (EP,US); C07K16/18 (EP,US); C07K16/40 (US);
G01N33/68 (US); C12Y301/03048 (US); G01N2500/02 (EP,US) (-)
Former IPC [2015/23]C07K16/40, G01N33/573, A61K39/395, A61P37/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/23]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:PTPRS UND PROTEOGLYKANE BEI AUTOIMMUNKRANKHEITEN[2015/23]
English:PTPRS AND PROTEOGLYCANS IN AUTOIMMUNE DISEASE[2015/23]
French:PTPRS ET PROTÉOGLYCANES DANS UNE MALADIE AUTO-IMMUNE[2015/23]
Entry into regional phase23.02.2015National basic fee paid 
23.02.2015Search fee paid 
23.02.2015Designation fee(s) paid 
23.02.2015Examination fee paid 
Examination procedure23.02.2015Examination requested  [2015/23]
07.10.2016Amendment by applicant (claims and/or description)
08.03.2018Despatch of a communication from the examining division (Time limit: M06)
18.09.2018Reply to a communication from the examining division
17.10.2019Cancellation of oral proceeding that was planned for 21.10.2019
21.10.2019Date of oral proceedings (cancelled)
24.01.2020Communication of intention to grant the patent
03.06.2020Fee for grant paid
03.06.2020Fee for publishing/printing paid
03.06.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.03.2018
Opposition(s)16.04.2021No opposition filed within time limit [2021/25]
Fees paidRenewal fee
10.07.2015Renewal fee patent year 03
11.07.2016Renewal fee patent year 04
12.07.2017Renewal fee patent year 05
11.07.2018Renewal fee patent year 06
15.07.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.07.2013
AL15.07.2020
AT15.07.2020
CY15.07.2020
CZ15.07.2020
EE15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
MK15.07.2020
MT15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
LU23.07.2020
BG15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
[2022/32]
Former [2022/27]HU23.07.2013
AL15.07.2020
AT15.07.2020
CY15.07.2020
CZ15.07.2020
EE15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
MT15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
LU23.07.2020
BG15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/36]AL15.07.2020
AT15.07.2020
CZ15.07.2020
EE15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SI15.07.2020
SK15.07.2020
SM15.07.2020
LU23.07.2020
BG15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/28]AL15.07.2020
AT15.07.2020
CZ15.07.2020
EE15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SK15.07.2020
SM15.07.2020
LU23.07.2020
BG15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/25]AL15.07.2020
AT15.07.2020
CZ15.07.2020
EE15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SM15.07.2020
LU23.07.2020
BG15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/23]AT15.07.2020
CZ15.07.2020
EE15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
MC15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
SM15.07.2020
LU23.07.2020
BG15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/22]AT15.07.2020
CZ15.07.2020
EE15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
PL15.07.2020
RO15.07.2020
RS15.07.2020
LU23.07.2020
BG15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/20]AT15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
PL15.07.2020
RS15.07.2020
LU23.07.2020
BG15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/10]AT15.07.2020
HR15.07.2020
LT15.07.2020
LV15.07.2020
PL15.07.2020
RS15.07.2020
BG15.10.2020
GR16.10.2020
IS15.11.2020
PT16.11.2020
Former [2021/09]AT15.07.2020
LT15.07.2020
BG15.10.2020
GR16.10.2020
PT16.11.2020
Former [2021/07]LT15.07.2020
Documents cited:Search[IP]WO2012148003  (SBI BIOTECH CO LTD [JP], et al) [IP] 1-4 * paragraph [0021] * * paragraph [0044] - paragraph [0045] * * paragraph [0064] *;
 [IDA]  - C. H. COLES ET AL, "Proteoglycan-Specific Molecular Switch for RPTP Clustering and Neuronal Extension", SCIENCE, (20110331), vol. 332, no. 6028, doi:10.1126/science.1200840, ISSN 0036-8075, pages 484 - 488, XP055123971 [ID] 14,15 * abstract * [A] 1-13

DOI:   http://dx.doi.org/10.1126/science.1200840
 [T]  - K. M. DOODY ET AL, "Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy", SCIENCE TRANSLATIONAL MEDICINE, Washington, DC, (20150520), vol. 7, no. 288, doi:10.1126/scitranslmed.aaa4616, ISSN 1946-6234, pages 288ra76 - 288ra76, XP055253889

DOI:   http://dx.doi.org/10.1126/scitranslmed.aaa4616
 [T]  - STANFORD STEPHANIE M ET AL, "Receptor Protein Tyrosine Phosphatase [alpha]-Mediated Enhancement of Rheumatoid Synovial Fibroblast Signaling and Promotion of Arthritis in Mice.", ARTHRITIS & RHEUMATOLOGY (HOBOKEN, N.J.) FEB 2016, (20160201), vol. 68, no. 2, ISSN 2326-5205, pages 359 - 369, XP009188793
 [T]  - STANFORD STEPHANIE M ET AL, "TGF beta responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasiveness", ANNALS OF THE RHEUMATIC DISEASES, (201601), vol. 75, no. 1, doi:10.1136/ANNRHEUMDIS-2014-205790, pages 295 - 302, XP009188802

DOI:   http://dx.doi.org/10.1136/annrheumdis-2014-205790
 [AP]  - STEPHANIE M. STANFORD ET AL, "Protein Tyrosine Phosphatase Expression Profile of Rheumatoid Arthritis Fibroblast-like Synoviocytes: A Novel Role of SH2 Domain-Containing Phosphatase 2 as a Modulator of Invasion and Survival", ARTHRITIS & RHEUMATISM, US, (20130523), vol. 65, no. 5, doi:10.1002/art.37872, ISSN 0004-3591, pages 1171 - 1180, XP055253976 [AP] 1-15

DOI:   http://dx.doi.org/10.1002/art.37872
 [AD]  - Y. SHEN ET AL, "PTP Is a Receptor for Chondroitin Sulfate Proteoglycan, an Inhibitor of Neural Regeneration", SCIENCE, (20091015), vol. 326, no. 5952, doi:10.1126/science.1178310, ISSN 0036-8075, pages 592 - 596, XP055123975 [AD] 1-15

DOI:   http://dx.doi.org/10.1126/science.1178310
International search[A]WO2007041317  (VIRAL LOGIC SYSTEMS TECHNOLOGY [US], et al);
 [Y]WO2011097327  (JOLLA INST FOR ALLERGY & IMMUNOLOGY [US], et al);
 [Y]  - COLES, CHARLOTTE H. ET AL., "Proteoglycan-specific molecular switch for RPTP clustering and neuronal extension", SCIENCE, (2011), vol. 332, no. 6028, pages 484 - 488, XP055123971

DOI:   http://dx.doi.org/10.1126/science.1200840
 [A]  - NIKOLAIENKO, ROMAN M. ET AL., "Receptor protein tyrosine phosphatases and cancer: new insights from structural biology", CELL ADHESION & MIGRATION, (20120701), vol. 6, no. 4, pages 356 - 364, XP055190228

DOI:   http://dx.doi.org/10.4161/cam.21242
 [A]  - MOHEBIANY, ALMA N. ET AL., "Receptor-type tyrosine phosphatase ligands: looking for the needle in the haystack", THE FEBS JOURNAL, (20120705), vol. 280, no. 2, pages 388 - 400, XP055190229

DOI:   http://dx.doi.org/10.1111/j.1742-4658.2012.08653.x
by applicantEP0003089
 EP0173494
 WO8702671
 US4676980
 US4816567
 US4946778
 WO9100360
 US5034506
 US5143854
 WO9220373
 WO9308829
 US5235033
 WO9617958
 US5530101
 US5545807
 US5545806
 US5569825
 US5585089
 US5625126
 US5633425
 US5661016
 US5693761
 US5693762
 US5777085
 US5859205
 WO9907409
 WO9932619
 WO0001846
 WO0044895
 WO0044914
 US6180370
 US6210671
 WO0129058
 WO0136646
 US6329511
 US2002160393
 US2003027783
 US6573099
 WO2012148003
    - COLES et al., Science, (20110000), vol. 332, pages 484 - 488
    - SHEN et al., Science, (20091023), pages 592 - 596
    - COLES et al., Science, (20110422), pages 484 - 488
    - LIEBERMAN, Pharmaceutical Dosage Forms, (19920000), vol. 1-3
    - "Carbohydrate Modifications in Antisense Research", ECKSTEIN, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press
    - LEICHER et al., J. Biol. Chem., (19980000), vol. 273, no. 52, pages 35095 - 35101
    - FODOR, Science, (19910000), pages 767 - 773
    - JOHNSTON, Curr. Biol., (19980000), vol. 8, pages R171 - R174
    - SCHUMMER, Biotechniques, (19970000), vol. 23, pages 1087 - 1092
    - SMITHWATERMAN, Adv. Appl. Math., (19810000), vol. 2, page 482
    - NEEDLEMANWUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443
    - PEARSONLIPMAN, Proc. Nat'l. Acad. Sci. USA, (19880000), vol. 85, page 2444
    - LONBERGHUSZAR, Intern. Rev. Immunol., (19950000), vol. 13, pages 65 - 93
    - ALTSCHUL et al., Nuc. Acids Res., (19770000), vol. 25, pages 3389 - 3402
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410
    - MARCOS, P., Biochemical and Biophysical Research Communications, (20070000), vol. 358, pages 521 - 527
    - WEINTRAUB, Scientific American, (19900000), vol. 262, page 40
    - MARCUS-SAKURA, Anal. Biochem., (19880000), vol. 172, page 289
    - FRALEY et al., Trends Biochem. Sci., (19810000), vol. 6, page 77
    - ELBASHIR et al., Nature, (20010000), vol. 411, pages 494 - 498
    - TUSCHLBORKHARDT, Molecular Interventions, (20020000), vol. 2, page 158
    - THORPE et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., (19820000), vol. 62, doi:10.1111/j.1600-065X.1982.tb00392.x, pages 119 - 58, XP001179872

DOI:   http://dx.doi.org/10.1111/j.1600-065X.1982.tb00392.x
    - FISHWILD et al., Nature Biotechnology, (19960000), vol. 14, pages 826 - 51
    - MCCAFFERTY et al., Nature, (19900000), vol. 348, pages 552 - 554
    - KOHLERMILSTEIN, Nature, (19750000), vol. 256, pages 495 - 497
    - KOZBOR et al., Immunology Today, (19830000), vol. 4, page 72
    - "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", ARNON et al., Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., (19850000), pages 243 - 56
    - VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536
    - SURESH et al., Methods in Enzymology, (19860000), vol. 121, page 210
    - MARKS et al., Bio/Technology, (19920000), vol. 10, pages 779 - 783
    - LONBERG et al., Nature, (19940000), vol. 368, pages 812 - 859
    - MARKS et al., Biotechnology, (19920000), vol. 10, pages 779 - 783
    - TRAUNECKER et al., EMBO J., (19910000), vol. 10, pages 3655 - 3659
    - JONES et al., Nature, (19860000), vol. 321, pages 522 - 525
    - WINTERMILSTEIN, Nature, (19910000), vol. 349, page 293
    - MORRISON et al., PNAS USA, (19840000), vol. 81, pages 6851 - 6855
    - RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 327
    - MORRISONOI, Adv. Immunol., (19880000), vol. 44, pages 65 - 92
    - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596
    - PADLAN, Molec. Immun., (19910000), vol. 28, pages 489 - 498
    - PADLAN, Molec. Immun., (19940000), vol. 31, no. 3, pages 169 - 217
    - HELLSTROM et al., Antibodies For Drug Delivery''in Controlled Drug Delivery, Marcel Dekker, Inc., (19870000), pages 623 - 53
    - "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", THORPE et al., Monoclonal Antibodies '84: Biological And Clinical Applications, (19850000), pages 475 - 506
    - BERGE et al., Journal of Pharmaceutical Science, (19770000), vol. 66, pages 1 - 19
    - WANG et al., Nat Rev Genet., (20090000), vol. 10, no. 1, pages 57 - 63
    - MARTIN, Nat Rev Genet., (20110000), vol. 12, no. 10, pages 671 - 82
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.